

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10583419
	Filing Date		2007-09-28
	First Named Inventor	Christian Hubschwerlen	
	Art Unit	1625	
	Examiner Name	R. J. Desai	
	Attorney Docket Number	65507(41925)	

U.S.PATENTS						Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
RD	1	5808076		1998-09-15	Vetter et al.	
RD	2	5998436		1999-12-07	Yazaki et al.	
RD	3	5491139		1996-02-13	Demuth, Jr. et al.	
RD	4	4840956		1989-06-20	Domagala et al.	
RD	5	5221676		1993-06-22	Laborde et al.	
RD	6	6239152		2001-05-29	Gordeev et al.	
RD	7	5861413		1999-01-19	Habich et al.	
If you wish to add additional U.S. Patent citation information please click the Add button.						Add
U.S.PATENT APPLICATION PUBLICATIONS						Remove

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number	10583419
Filing Date	2007-09-28
First Named Inventor	Christian Hubschwerlen
Art Unit	1625
Examiner Name	R. J. Desai
Attorney Docket Number	65507(41925)

Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
RD	1	20040132764		2004-07-08	Locher	

If you wish to add additional U.S. Published Application citation information please click the Add button. [Add](#)

FOREIGN PATENT DOCUMENTS

[Remove](#)

Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T ⁵
RD	1	93/09103	WO	A1	1993-05-13	Upjohn Co		<input type="checkbox"/>
RD	2	2004/069816	WO	A1	2004-08-19	Ranbaxy Lab Ltd et al.		<input type="checkbox"/>
RD	3	2001/09107	WO	A1	2001-02-08	Upjohn Co et al.		<input type="checkbox"/>
RD	4	2000/10566	WO	A1	2000-03-02	Squibb Bristol Myers Co		<input type="checkbox"/>
RD	5	2167873	RU	C2	2001-05-27	Vakunaga Farmas Jutikal Ko Ltd		<input checked="" type="checkbox"/>
RD	6	196 01 265	DE	A1	1997-07-17	Bayer Ag		<input checked="" type="checkbox"/>
RD	7	2069478	JP	A	1990-03-08	Sagami Chem Res et al.		<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10583419
Filing Date	2007-09-28
First Named Inventor	Christian Hubschwerlen
Art Unit	1625
Examiner Name	R. J. Desai
Attorney Docket Number	65507(41925)

RD	8	0 266 576	EP	A2	1988-05-11	Bristol Myers Co	<input type="checkbox"/>
RD	9	0 390 215	EP	A2	1990-10-03	Wakunaga Seiyaku Kk	<input type="checkbox"/>
RD	10	97/30995	WO	A1	1997-08-28	Zeneca Ltd et al.	<input type="checkbox"/>
RD	11	99/28317	WO	A1	1999-06-10	Zeneca Ltd et al.	<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵
RD	1	Patani et al., "Bioisosterism: A Rational Approach in Drug Design", Chem. Rev., 1996, pgs. 3147-3176.	<input type="checkbox"/>
	2	Hcaplus 138:338143	<input type="checkbox"/>
	3	Hcaplus 138:304289	<input type="checkbox"/>
	4	Hcaplus 138:304288	<input type="checkbox"/>
RD	5	Weidner-Wells et al., Bioorg. Med. Chem., 10(7), pgs. 2345-2351 (2002).	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10583419
Filing Date	2007-09-28
First Named Inventor	Christian Hubschwerlen
Art Unit	1625
Examiner Name	R. J. Desai
Attorney Docket Number	65507(41925)

RD	6	Weidner-Wells et al., Bioorg. Med. Chem. Lett., 11(14), pgs. 1829-1832 (2001).	<input type="checkbox"/>
RD	7	Hubschwerlen et al., "Structure-Activity Relationship in the Oxazolidinone-Quinolone Hybrid Series: Influence of the Central Spacer on the Antibacterial Activity and the Mode of Action", Bioorganic & Medicinal Chemistry Letters (2003), pgs. 4229-4233.	<input type="checkbox"/>
	8	Hcaplus 141:395540	<input type="checkbox"/>
RD	9	Selvakumar et al., "Influence of Ethylene-Oxy Spacer Group on the Activity of Linezolid: Synthesis of Potent Antiberials Possessing a Thiocarbonyl Group", Bioorganic & Medicinal Chemistry Letters, 13 (2003), pgs. 4169-4172 (August 2003).	<input type="checkbox"/>
RD	10	Hcaplus 141:207195, A preparation of (oxazolidinylmethyl) acetamide derivatives, useful as antimicrobial agents", August 19, 2004, Mehta et al.	<input type="checkbox"/>
RD	11	Manfred E. Wolff et al., "Burger's Medicinal Chemistry, 5ed, Part 1" John Wiley & Sons, 1995, pgs. 975-977.	<input type="checkbox"/>
RD	12	G.S. Banker et al., "Modern Pharmaceutics, 3ed." Marcel Dekker, New York, 1996, pgs. 451 and 596.	<input type="checkbox"/>
RD	13	Hawley's Condensed Chemical Dictionary (1993), pg. 594	<input type="checkbox"/>
RD	14	.W.A. Gregory et al., "Antibacterials. Synthesis and Structure-Activity Studies of 3-Aryl-2-oxooxazolidines. 1. The "B" Group", J. Med. Chem. 32, pgs. 1673-1681 (1989).	<input type="checkbox"/>
RD	15	R.T. Morrison et al., Lehrbuch der Organischen Chemie, 3, Auflage, 1986, pgs. 38-39.	<input type="checkbox"/>
	16	Rompp Chemie Lexikon, 9 auflage, pgs. 1892-1893	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10583419
Filing Date	2007-09-28
First Named Inventor	Christian Hubschwerlen
Art Unit	1625
Examiner Name	R. J. Desai
Attorney Docket Number	65507(41925)

RD	17	Abstract of Japanese Published Application No. JP200516239, published 12/05/2000	<input type="checkbox"/>
RD	18	Dalhoff, A., "Symposium: Multiple Mode of Action Antibiotics - The Quinolone-Plus Approach", ICAAC2007, Sept. 17-20, 2007, Chicago.	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button **Add**

EXAMINER SIGNATURE

Examiner Signature	/Rita Desai/	Date Considered	4/15/2011
--------------------	--------------	-----------------	-----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.